Synopsis
Synopsis
0
CEP/COS
0
NDC API
0
VMF
0
API
0
FDF
0
FDA Orange Book
0
Canada
0
Australia
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Kw 4354
2. Kw-4354
3. Oxatimide
4. R 35443
5. R35443
6. Tinset
1. 60607-34-3
2. Tinset
3. Celtect
4. Cobiona
5. Dasten
6. Kw-4354
7. 3-[3-(4-benzhydrylpiperazin-1-yl)propyl]-1h-benzimidazol-2-one
8. 1-[3-[4-(diphenylmethyl)-1-piperazinyl]propyl]-1,3-dihydro-2h-benzimidazol-2-one
9. R-35443
10. R 35,443
11. 1-(3-(4-benzhydrylpiperazin-1-yl)propyl)-1h-benzo[d]imidazol-2(3h)-one
12. Oxatimide
13. Nsc-309710
14. 1-(3-(4-(diphenylmethyl)-1-piperazinyl)propyl)-2-benzimidazolinone
15. J31il9z2ee
16. 1-(3-(4-(diphenylmethyl)-1-piperazinyl)propyl)-1,3-dihydro-2h-benzimidazol-2-one
17. Mls000028549
18. Oxatomidum
19. Oxatomida
20. Ncgc00015774-03
21. Smr000058301
22. 1-[3-[4-(diphenylmethyl)-1-piperazinyl]propyl]-2-benzimidazolinone
23. Oxatomidum [inn-latin]
24. 2h-benzimidazol-2-one, 1-(3-(4-(diphenylmethyl)-1-piperazinyl)propyl)-1,3-dihydro-
25. Dsstox_cid_25181
26. Dsstox_rid_80729
27. Dsstox_gsid_45181
28. Oxatomida [inn-spanish]
29. Mcn-jr 35443
30. R 35443
31. Celtect (tn)
32. Cas-60607-34-3
33. Einecs 262-320-9
34. Cbmicro_024634
35. Unii-j31il9z2ee
36. Brn 4724760
37. Oxatomide (jan/usan/inn)
38. 1-{3-[4-(diphenylmethyl)-1-piperazinyl]propyl}-1,3-dihydro-2h-benzimidazol-2-one
39. Oxatomide [usan:inn:ban:jan]
40. Oxatomide, >=99%
41. Oxatomide [inn]
42. Oxatomide [jan]
43. Oxatomide [mi]
44. Oxatomide [usan]
45. Lopac-o-9387
46. Oxatomide [mart.]
47. O 9387
48. Cid_4615
49. Oxatomide [who-dd]
50. Lopac0_000924
51. Oprea1_338592
52. Regid_for_cid_4615
53. Schembl28824
54. Chembl13828
55. Dtxsid4045181
56. Bdbm76863
57. Chebi:31943
58. Hms2089n07
59. Hms2231h12
60. Hms3372k08
61. Tox21_110219
62. Ccg-11811
63. Nsc309710
64. Nsc771641
65. Zinc19632896
66. Akos000507212
67. Tox21_110219_1
68. Ab04841
69. Db12877
70. Ks-1375
71. Nsc 309710
72. Nsc-771641
73. 2h-benzimidazol-2-one, 1,3-dihydro-1-(3-(4-(diphenylmethyl)-1-piperazinyl)propyl)-
74. Ncgc00015774-01
75. Ncgc00015774-02
76. Ncgc00015774-04
77. Ncgc00015774-05
78. Ncgc00015774-06
79. Ncgc00094235-01
80. Ncgc00094235-02
81. Bim-0024581.p001
82. Db-053668
83. Hy-123205
84. Cs-0081837
85. Eu-0100924
86. Ft-0630723
87. D01773
88. Ab01227629-02
89. 607o343
90. A832804
91. Sr-01000076051
92. Q2071515
93. Sr-01000076051-1
94. W-105243
95. 3-[3-(4-benzhydrylpiperazino)propyl]-1h-benzimidazol-2-one
96. 3-[3-[4-(diphenylmethyl)-1-piperazinyl]propyl]-1h-benzimidazol-2-one
97. 3-[3-[4-(diphenylmethyl)piperazin-1-yl]propyl]-1h-benzimidazol-2-one
98. 1-[3-(4-benzhydrylpiperazin-1-yl)propyl]-1,3-dihydro-2h-benzimidazol-2-one
99. 1-{3-[4-(diphenylmethyl)-1-piperazinyl}-propyl}-1,3-dihydro-2h-benzimidazol-2-one
100. 1{-[4-(diphenylmethyl)-1-piperzinyl]propyl}-1,3-dihydro-2h-benzimidazol-2-one
| Molecular Weight | 426.6 g/mol |
|---|---|
| Molecular Formula | C27H30N4O |
| XLogP3 | 4.1 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 7 |
| Exact Mass | 426.24196159 g/mol |
| Monoisotopic Mass | 426.24196159 g/mol |
| Topological Polar Surface Area | 38.8 Ų |
| Heavy Atom Count | 32 |
| Formal Charge | 0 |
| Complexity | 575 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Anti-Asthmatic Agents
Drugs that are used to treat asthma. (See all compounds classified as Anti-Asthmatic Agents.)
Histamine H1 Antagonists
Drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonize or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. The effects of blocking central nervous system H1 receptors are not as well understood. (See all compounds classified as Histamine H1 Antagonists.)
Anti-Allergic Agents
Agents that are used to treat allergic reactions. Most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (From AMA Drug Evaluations Annual, 1994, p475) (See all compounds classified as Anti-Allergic Agents.)
R - Respiratory system
R06 - Antihistamines for systemic use
R06A - Antihistamines for systemic use
R06AE - Piperazine derivatives
R06AE06 - Oxatomide
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
INTERMEDIATES SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Global Sales Information
ABOUT THIS PAGE
We have 3 companies offering MolPort-001-964-500
Get in contact with the supplier of your choice:
LOOKING FOR A SUPPLIER?
Market Place
